{"entity":{"id":"nct05973773","kind":"trial","name":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","aka":["REZILIENT3"],"tldr":"A phase 3 trial testing Zipalertinib in non-small-cell lung cancer, active and no longer recruiting.","summary":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumours) is a phase 3 interventional study registered as NCT05973773, led by Taiho Oncology, and active but no longer recruiting on the registry. Official title: Randomised, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations. Planned enrolment is 285 participants (actual). The study started in 2023-12-18 and primary completion is expected in 2027-05-27. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05973773","url":"https://clinicaltrials.gov/study/NCT05973773"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["zipalertinib"],"companies":["taiho-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05973773","phase":"3","setting":"Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations","sponsor":"Taiho Oncology","started":"2023-12-18","startedType":"actual","enrolled":285,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05973773/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/"}],"company":[{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/"}]}}